Cleared Traditional

RECLINING GERI CHAIRS W/CASTERS & LAP TRAY (K933000) - FDA 510(k) Clearance

Class I Physical Medicine device.

K933000 · Winco, Inc. · Physical Medicine device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1993
Decision
104d
Days
Class 1
Risk

K933000 is an FDA 510(k) clearance for the RECLINING GERI CHAIRS W/CASTERS & LAP TRAY. Classified as Chair, With Casters (product code INM), Class I - General Controls.

Submitted by Winco, Inc. (Ocala, US). The FDA issued a Cleared decision on September 30, 1993 after a review of 104 days - within the typical 510(k) review window.

This device falls under the Physical Medicine FDA review panel, regulated under 21 CFR 890.3100 - the FDA physical medicine device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Physical Medicine review framework, consistent with the majority of Class II 510(k) submissions.

View all Winco, Inc. devices

Submission Details

510(k) Number K933000 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 18, 1993
Decision Date September 30, 1993
Days to Decision 104 days
Submission Type Traditional
Review Panel Physical Medicine (PM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
11d faster than avg
Panel avg: 115d · This submission: 104d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code INM Chair, With Casters
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 890.3100
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.